First 45 U.S. Volunteers Get Experimental COVID-19 Vaccine

The investigational vaccine doesn't contain any part of the actual coronavirus and cannot cause infection, but instead includes a short segment of lab-grown messenger RNA.

Grow Your Business, Not Your Inbox

Stay informed and join our daily newsletter now!
Will be used in accordance with our Privacy Policy
First 45 U.S. Volunteers Get Experimental COVID-19 Vaccine
Image credit: via PC Mag
Reporter at PCMag
2 min read
This story originally appeared on PC Mag

Scientists on Monday gave the first-ever injection of an experimental coronavirus vaccine to volunteers in the US.

Doses of mRNA-1273 into the arms of healthy participants at Kaiser Permanente Washington Research Institute (KPWHRI) this week began the first-stage study of a potential COVID-19 immunization. The initial trial involves 45 people aged 18 to 55, including tech company operations manager Jennifer Haller—the study's first participant.

"We all feel so helpless. This is an amazing opportunity for me to do something," the 43-year-old Seattelite told the Associated Press before getting jabbed. She reportedly left the exam room with a smile, "feeling great."

The investigational vaccine, made by biotech company Moderna, does not contain any part of the actual coronavirus and cannot cause infection. It instead includes a short segment of lab-grown messenger RNA. Researchers are currently testing the safety of various doses to learn whether they produce an immune response. They will keep an eye on any side effects and draw blood samples to look for clues.

"We don't know whether this vaccine will induce an immune response or whether it will be safe. That's why we're doing a trial," Kaiser Permanente study leader Lisa Jackson said in a statement to the AP. Efficiency in preventing COVID-19 will be determined at a later phase.

Even if all goes well, a vaccine will not be available for widespread use for another 12 to 18 months, according to Anthony Fauci of the U.S. National Institute of Health. Still, "going from not even knowing that this virus was out there … to have any vaccine" in testing in about two months is unprecedented, Jackson said.

KPWHRI's vaccine research team previously conducted similar trials in the fight against "swine" (H1N1) and "bird" (influenza A) flu.

More from Entrepreneur

Get heaping discounts to books you love delivered straight to your inbox. We’ll feature a different book each week and share exclusive deals you won’t find anywhere else.
Jumpstart Your Business. Entrepreneur Insider is your all-access pass to the skills, experts, and network you need to get your business off the ground—or take it to the next level.
Starting, buying, or growing your small business shouldn’t be hard. Guidant Financial works to make financing easy for current and aspiring small business owners by providing custom funding solutions, financing education, and more.

Latest on Entrepreneur

Entrepreneur Media, Inc. values your privacy. In order to understand how people use our site generally, and to create more valuable experiences for you, we may collect data about your use of this site (both directly and through our partners). By continuing to use this site, you are agreeing to the use of that data. For more information on our data policies, please visit our Privacy Policy.